125316-60-1 Usage
Description
CD437, also known as 6-phenylnaphthylene-2-carboxyic acid, is a naphthoic acid derivative featuring a phenyl substituent with adamant-1-yl and hydroxy groups at positions 3 and 4, respectively. It is a yellow solid that acts as a selective agonist of the retinoic acid receptor (RAR) gamma, playing a crucial role in inducing cell cycle arrest and apoptosis in various cancer cells.
Uses
Used in Pharmaceutical Industry:
CD437 is used as an intermediate in the preparation of Adapalene derivatives, which are significant in the development of pharmaceuticals targeting various skin conditions and cancer treatments.
Used in Cancer Treatment:
CD437 is utilized as a therapeutic agent for cancer treatment, particularly as a selective agonist of the retinoic acid receptor (RAR) gamma. Its action leads to cell cycle arrest and apoptosis in a range of cancer cells, making it a promising candidate for cancer research and treatment.
Used in Drug Synthesis:
As a key intermediate in the synthesis of Adapalene and its derivatives, CD437 plays a vital role in the pharmaceutical industry for developing new drugs with potential applications in treating various health conditions, including skin disorders and cancer.
Biological Activity
Synthetic retinoid that is an RAR γ -selective agonist. Displays RAR γ -dependent and -independent effects on differentiation and apoptosis.
Biochem/physiol Actions
CD437 is a retinoic acid receptor (RAR)γ-selective agonist, γ-selective retinoid; potent inducer of apoptosis.
Check Digit Verification of cas no
The CAS Registry Mumber 125316-60-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,3,1 and 6 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 125316-60:
(8*1)+(7*2)+(6*5)+(5*3)+(4*1)+(3*6)+(2*6)+(1*0)=101
101 % 10 = 1
So 125316-60-1 is a valid CAS Registry Number.
InChI:InChI=1/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)
125316-60-1Relevant articles and documents
DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS
-
, (2011/01/12)
Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris.
Emulsions comprising at least one retinoid and benzoyl peroxide
-
, (2009/12/28)
Stable dermatological/cosmetic emulsions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one fatty phase, at least one hydrophilic phase and at least one emulsifier.
Retinoid inhibition of expression of VEGF
-
, (2008/06/13)
The retinoids, in particular the anti-AP-1 retinoids, effectively inhibit the expression of VEGF, and thus are useful for the therapeutic treatment of disease states manifesting an overexpression of VEGF.
